1
|
Sun T, Krishnan V, Pan DC, Filippov SK, Ravid S, Sarode A, Kim J, Zhang Y, Power C, Aday S, Guo J, Karp JM, McDannold NJ, Mitragotri SS. Ultrasound-mediated delivery of flexibility-tunable polymer drug conjugates for treating glioblastoma. Bioeng Transl Med 2023; 8:e10408. [PMID: 36925708 PMCID: PMC10013755 DOI: 10.1002/btm2.10408] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 05/07/2022] [Accepted: 05/14/2022] [Indexed: 11/21/2022] Open
Abstract
Effective chemotherapy delivery for glioblastoma multiforme (GBM) is limited by drug transport across the blood-brain barrier and poor efficacy of single agents. Polymer-drug conjugates can be used to deliver drug combinations with a ratiometric dosing. However, the behaviors and effectiveness of this system have never been well investigated in GBM models. Here, we report flexible conjugates of hyaluronic acid (HA) with camptothecin (CPT) and doxorubicin (DOX) delivered into the brain using focused ultrasound (FUS). In vitro toxicity assays reveal that DOX-CPT exhibited synergistic action against GBM in a ratio-dependent manner when delivered as HA conjugates. FUS is employed to improve penetration of DOX-HA-CPT conjugates into the brain in vivo in a murine GBM model. Small-angle x-ray scattering characterizations of the conjugates show that the DOX:CPT ratio affects the polymer chain flexibility. Conjugates with the highest flexibility yield the highest efficacy in treating mouse GBM in vivo. Our results demonstrate the association of FUS-enhanced delivery of combination chemotherapy and the drug-ratio-dependent flexibility of the HA conjugates. Drug ratio in the polymer nanocomplex may thus be employed as a key factor to modulate FUS drug delivery efficiency via controlling the polymer flexibility. Our characterizations also highlight the significance of understanding the flexibility of drug carriers in ultrasound-mediated drug delivery systems.
Collapse
Affiliation(s)
- Tao Sun
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA.,Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
| | - Vinu Krishnan
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA
| | - Daniel C Pan
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA
| | - Sergey K Filippov
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Present address: Pharmaceutical Sciences Laboratory Åbo Akademi University, Turku Bioscience Turku Finland
| | - Sagi Ravid
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
| | - Apoorva Sarode
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA
| | - Jayoung Kim
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA
| | - Yongzhi Zhang
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
| | - Chanikarn Power
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
| | - Sezin Aday
- Department of Anesthesiology Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.,Center for Nanomedicine, Harvard Stem Cell Institute, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.,Harvard-MIT Division of Health Sciences and Technology Cambridge Massachusetts USA.,Proteomics Platform, Broad Institute of MIT and Harvard Cambridge Massachusetts USA
| | - Junling Guo
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA.,Present address: College of Biomass Science and Engineering Sichuan University Chengdu Sichuan China
| | - Jeffrey M Karp
- Department of Anesthesiology Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.,Center for Nanomedicine, Harvard Stem Cell Institute, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.,Harvard-MIT Division of Health Sciences and Technology Cambridge Massachusetts USA.,Proteomics Platform, Broad Institute of MIT and Harvard Cambridge Massachusetts USA
| | - Nathan J McDannold
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
| | - Samir S Mitragotri
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University Boston Massachusetts USA
| |
Collapse
|
2
|
Aday S, Li W, Karp JM, Joshi N. An in vitro Blood-brain Barrier Model to Study the Penetration of Nanoparticles. Bio Protoc 2022; 12:e4334. [DOI: 10.21769/bioprotoc.4334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 11/02/2021] [Accepted: 01/16/2022] [Indexed: 11/02/2022] Open
|
3
|
Li W, Qiu J, Li XL, Aday S, Zhang J, Conley G, Xu J, Joseph J, Lan H, Langer R, Mannix R, Karp JM, Joshi N. BBB pathophysiology-independent delivery of siRNA in traumatic brain injury. Sci Adv 2021; 7:7/1/eabd6889. [PMID: 33523853 DOI: 10.1101/2020.06.26.173393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 11/03/2020] [Indexed: 05/23/2023]
Abstract
Small interfering RNA (siRNA)-based therapeutics can mitigate the long-term sequelae of traumatic brain injury (TBI) but suffer from poor permeability across the blood-brain barrier (BBB). One approach to overcoming this challenge involves treatment administration while BBB is transiently breached after injury. However, it offers a limited window for therapeutic intervention and is applicable to only a subset of injuries with substantially breached BBB. We report a nanoparticle platform for BBB pathophysiology-independent delivery of siRNA in TBI. We achieved this by combined modulation of surface chemistry and coating density on nanoparticles, which maximized their active transport across BBB. Engineered nanoparticles injected within or outside the window of breached BBB in TBI mice showed threefold higher brain accumulation compared to nonengineered PEGylated nanoparticles and 50% gene silencing. Together, our data suggest that this nanoparticle platform is a promising next-generation drug delivery approach for the treatment of TBI.
Collapse
Affiliation(s)
- Wen Li
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - Jianhua Qiu
- Harvard Medical School, Boston, MA 02115, USA
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Xiang-Ling Li
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Sezin Aday
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jingdong Zhang
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Grace Conley
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Jun Xu
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - John Joseph
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - Haoyue Lan
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Robert Langer
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Rebekah Mannix
- Harvard Medical School, Boston, MA 02115, USA.
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Jeffrey M Karp
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Harvard Medical School, Boston, MA 02115, USA
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Broad Institute, Cambridge, MA 02142, USA
- Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | - Nitin Joshi
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
4
|
Li W, Qiu J, Li XL, Aday S, Zhang J, Conley G, Xu J, Joseph J, Lan H, Langer R, Mannix R, Karp JM, Joshi N. BBB pathophysiology-independent delivery of siRNA in traumatic brain injury. Sci Adv 2021; 7:eabd6889. [PMID: 33523853 PMCID: PMC7775748 DOI: 10.1126/sciadv.abd6889] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 11/03/2020] [Indexed: 05/02/2023]
Abstract
Small interfering RNA (siRNA)-based therapeutics can mitigate the long-term sequelae of traumatic brain injury (TBI) but suffer from poor permeability across the blood-brain barrier (BBB). One approach to overcoming this challenge involves treatment administration while BBB is transiently breached after injury. However, it offers a limited window for therapeutic intervention and is applicable to only a subset of injuries with substantially breached BBB. We report a nanoparticle platform for BBB pathophysiology-independent delivery of siRNA in TBI. We achieved this by combined modulation of surface chemistry and coating density on nanoparticles, which maximized their active transport across BBB. Engineered nanoparticles injected within or outside the window of breached BBB in TBI mice showed threefold higher brain accumulation compared to nonengineered PEGylated nanoparticles and 50% gene silencing. Together, our data suggest that this nanoparticle platform is a promising next-generation drug delivery approach for the treatment of TBI.
Collapse
Affiliation(s)
- Wen Li
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - Jianhua Qiu
- Harvard Medical School, Boston, MA 02115, USA
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Xiang-Ling Li
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Sezin Aday
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jingdong Zhang
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Grace Conley
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Jun Xu
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - John Joseph
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Harvard Medical School, Boston, MA 02115, USA
| | - Haoyue Lan
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Robert Langer
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Rebekah Mannix
- Harvard Medical School, Boston, MA 02115, USA.
- Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
| | - Jeffrey M Karp
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Harvard Medical School, Boston, MA 02115, USA
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Broad Institute, Cambridge, MA 02142, USA
- Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | - Nitin Joshi
- Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
5
|
Shearn AIU, Aday S, Ben-Aicha S, Carnell-Morris P, Siupa A, Angelini GD, Clayton A, Boulanger C, Punjabi P, Emanueli C, Biglino G. Analysis of Neat Biofluids Obtained During Cardiac Surgery Using Nanoparticle Tracking Analysis: Methodological Considerations. Front Cell Dev Biol 2020; 8:367. [PMID: 32528952 PMCID: PMC7262431 DOI: 10.3389/fcell.2020.00367] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Accepted: 04/24/2020] [Indexed: 01/15/2023] Open
Abstract
Small extracellular vesicles (sEVs) are those nanovesicles 30-150 nm in size with a role in cell signalling and potential as biomarkers of disease. Nanoparticle tracking analysis (NTA) techniques are commonly used to measure sEV concentration in biofluids. However, this quantification technique can be susceptible to sample handing and machine settings. Moreover, some classes of lipoproteins are of similar sizes and could therefore confound sEV quantification, particularly in blood-derived preparations, such serum and plasma. Here we have provided methodological information on NTA measurements and systematically investigated potential factors that could interfere with the reliability and repeatability of results obtained when looking at neat biofluids (i.e., human serum and pericardial fluid) obtained from patients undergoing cardiac surgery and from healthy controls. Data suggest that variables that can affect vesicle quantification include the level of contamination from lipoproteins, number of sample freeze/thaw cycles, sample filtration, using saline-based diluents, video length and keeping the number of particles per frame within defined limits. Those parameters that are of less concern include focus, the "Maximum Jump" setting and the number of videos recorded. However, if these settings are clearly inappropriate the results obtained will be spurious. Similarly, good experimental practice suggests that multiple videos should be recorded. In conclusion, NTA is a perfectible, but still commonly used system for sEVs analyses. Provided users handle their samples with a highly robust and consistent protocol, and accurately report these aspects, they can obtain data that could potentially translate into new clinical biomarkers for diagnosis and monitoring of cardiovascular disease.
Collapse
Affiliation(s)
- Andrew I. U. Shearn
- Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom
| | - Sezin Aday
- Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom
| | - Soumaya Ben-Aicha
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | | | | | - Gianni D. Angelini
- Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom
| | - Aled Clayton
- School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Chantal Boulanger
- Cardiovascular Research Center, INSERM U970, Hôpital Européen Georges Pompidou, Paris, France
| | - Prakash Punjabi
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Costanza Emanueli
- Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - Giovanni Biglino
- Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| |
Collapse
|
6
|
Aday S, Halevy I, Anwar M, Madeddu P, Sahoo S, Petretto E, Peer D, Emanueli C. Abstract 130: Development of Bioinspired Synthetic Exosomes With Proangiogenic Potential. Circ Res 2019. [DOI: 10.1161/res.125.suppl_1.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Exosomes with variable microRNA cargos are released from different cell types and stimulate angiogenesis in animal models. Therefore, exosomes are currently considered for their potential to represent a safer and easier biological-based alternative to stem cell therapies. However, the limited amount of exosomes that can be reproducibly prepared from cultured stem cells and the complexity of the cargo of endogenous exosomes make them difficult to develop as off-the-shelf “pharmaceutical products” and limit their clinical potential. These issues could be surpassed by the use of artificial (i.e. nanoparticles mimicking the natural product) exosomes carrying a therapeutic cargo. In consideration of the possibility that not all cargo components of exosomes are required for their therapeutic functions, we reasoned that bioinspired artificial exosomes (AEs) incorporating key therapeutically relevant molecules and devoid of potentially negative or indifferent factors could further improve their therapeutic potential. Therefore, we developed and tested AEs containing exosomal proangiogenic miRNAs as a “proof-of-concept” for therapeutic angiogenesis. In order to achieve this, we: (1) characterized the common microRNA cargo of endogenous proangiogenic exosomes (from stem cells, pericytes and pericardial fluid) using bioinformatics, (2) exploited this knowledge to develop off-the-shelf artificial exosomes (AEs) with proangiogenic capacities, (3) validated the angiogenic potential of the bioinspired AEs. Bioinformatics analyses integrating data of miRNA arrays and panels of proangiogenic exosomes confirmed the enrichment of let-7 family in these exosomes. After testing the angiogenic potential of different members of let-7 family, we produced AEs containing let-7b (the most potent in the family) by microfluidic micromixing. The AEs were uptaken by human ECs cultured under hypoxic conditions, without causing toxicity. let-7b-AEs transferred functional let-7b, thus decreased the expression of validated targets of let-7b in recipient cells. let-7b-AEs improved EC survival, proliferation and angiogenesis
in vitro
and
in vivo
. These data suggest the therapeutic potential of bioinspired AEs containing let-7b.
Collapse
|
7
|
Besnier M, Gasparino S, Vono R, Sangalli E, Facoetti A, Bollati V, Cantone L, Zaccagnini G, Maimone B, Fuschi P, Da Silva D, Schiavulli M, Aday S, Caputo M, Madeddu P, Emanueli C, Martelli F, Spinetti G. miR-210 Enhances the Therapeutic Potential of Bone-Marrow-Derived Circulating Proangiogenic Cells in the Setting of Limb Ischemia. Mol Ther 2018; 26:1694-1705. [PMID: 29908843 DOI: 10.1016/j.ymthe.2018.06.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 06/05/2018] [Accepted: 06/05/2018] [Indexed: 12/28/2022] Open
Abstract
Therapies based on circulating proangiogenic cells (PACs) have shown promise in ischemic disease models but require further optimization to reach the bedside. Ischemia-associated hypoxia robustly increases microRNA-210 (miR-210) expression in several cell types, including endothelial cells (ECs). In ECs, miR-210 represses EphrinA3 (EFNA3), inducing proangiogenic responses. This study provides new mechanistic evidences for a role of miR-210 in PACs. PACs were obtained from either adult peripheral blood or cord blood. miR-210 expression was modulated with either an inhibitory complementary oligonucleotide (anti-miR-210) or a miRNA mimic (pre-miR-210). Scramble and absence of transfection served as controls. As expected, hypoxia increased miR-210 in PACs. In vivo, migration toward and adhesion to the ischemic endothelium facilitate the proangiogenic actions of transplanted PACs. In vitro, PAC migration toward SDF-1α/CXCL12 was impaired by anti-miR-210 and enhanced by pre-miR-210. Moreover, pre-miR-210 increased PAC adhesion to ECs and supported angiogenic responses in co-cultured ECs. These responses were not associated with changes in extracellular miR-210 and were abrogated by lentivirus-mediated EFNA3 overexpression. Finally, ex-vivo pre-miR-210 transfection predisposed PACs to induce post-ischemic therapeutic neovascularization and blood flow recovery in an immunodeficient mouse limb ischemia model. In conclusion, miR-210 modulates PAC functions and improves their therapeutic potential in limb ischemia.
Collapse
Affiliation(s)
- Marie Besnier
- Bristol Heart Institute, School of Clinical Science, University of Bristol, Bristol, UK
| | - Stefano Gasparino
- Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan, Italy
| | - Rosa Vono
- Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan, Italy
| | - Elena Sangalli
- Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan, Italy
| | - Amanda Facoetti
- Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan, Italy
| | - Valentina Bollati
- EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Laura Cantone
- EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Germana Zaccagnini
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato, Italy
| | - Biagina Maimone
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato, Italy
| | - Paola Fuschi
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato, Italy
| | - Daniel Da Silva
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato, Italy
| | - Michele Schiavulli
- AORN Santobono Pausilipon, Transfusion Medicine and Bone Marrow Transplantation Unit-Regional Reference Center for Coagulation Disorders, Napoli, Italy
| | - Sezin Aday
- Bristol Heart Institute, School of Clinical Science, University of Bristol, Bristol, UK
| | - Massimo Caputo
- Bristol Heart Institute, School of Clinical Science, University of Bristol, Bristol, UK
| | - Paolo Madeddu
- Bristol Heart Institute, School of Clinical Science, University of Bristol, Bristol, UK
| | - Costanza Emanueli
- Bristol Heart Institute, School of Clinical Science, University of Bristol, Bristol, UK; National Heart and Lung Institute, Imperial College London, London, UK
| | - Fabio Martelli
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato, Italy.
| | - Gaia Spinetti
- Laboratory of Cardiovascular Research, IRCCS MultiMedica, Milan, Italy.
| |
Collapse
|
8
|
Sargento-Freitas J, Aday S, Nunes C, Cordeiro M, Gouveia A, Silva F, Machado C, Rodrigues B, Santo GC, Ferreira C, Castelo-Branco M, Ferreira L, Cunha L. Endothelial Progenitor Cells influence acute and subacute stroke hemodynamics. J Neurol Sci 2018; 385:119-125. [DOI: 10.1016/j.jns.2017.12.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 12/01/2017] [Accepted: 12/22/2017] [Indexed: 01/29/2023]
|
9
|
Sargento-Freitas J, Aday S, Nunes C, Cordeiro M, Gouveia A, Silva F, Machado C, Rodrigues B, Santo GC, Ferreira C, Amorim A, Sousa S, Gomes AC, Castelo-Branco M, Ferreira L, Cunha L. Endothelial progenitor cells enhance blood-brain barrier permeability in subacute stroke. Neurology 2017; 90:e127-e134. [PMID: 29237797 DOI: 10.1212/wnl.0000000000004801] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 09/29/2017] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To study the association among endothelial progenitor cells (EPCs), subacute blood-brain barrier (BBB) permeability, and clinical outcome after ischemic stroke, determining the micro RNAs of EPCs responsible for good clinical outcome. METHODS We included consecutive patients with nonlacunar acute ischemic strokes in the territory of a middle cerebral artery and ages between 18 and 80 years. Clinical outcome was defined as modified Rankin Scale score at 3 months. Neuroimaging was performed at day 0 and 7 by MRI, including assessment of BBB permeability by dynamic contrast enhancement. EPCs were isolated from peripheral venous blood, quantified, and submitted to in vitro functional tests, including migratory and angiogenic assays. Stroke hemodynamics were evaluated serially by ultrasound. Statistical significance was set at p < 0.05. RESULTS We included 45 patients; mean age was 70.0 ± 10.0 years. The in vitro functional properties of EPCs were associated with BBB permeability, particularly at day 7. The number of each EPC subset at both timepoints was not associated with BBB permeability. Permeability of BBB at day 7 was independently associated with improved clinical outcome (odds ratio 0.897; 95% confidence interval 0.816-0.986; p = 0.025). The EPCs (CD34+ cell subset) of patients with good clinical outcome showed 24 differentially expressed miRNAs, with a common effect on adherens junction pathway. CONCLUSIONS The functional properties of EPCs are associated with enhanced subacute permeability of BBB and improved clinical outcome after acute ischemic stroke.
Collapse
Affiliation(s)
- João Sargento-Freitas
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Sezin Aday
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - César Nunes
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Miguel Cordeiro
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Ana Gouveia
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Fernando Silva
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Cristina Machado
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Bruno Rodrigues
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Gustavo Cordeiro Santo
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Carlos Ferreira
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - André Amorim
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Susana Sousa
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Ana Catarina Gomes
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Miguel Castelo-Branco
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal
| | - Lino Ferreira
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal.
| | - Luís Cunha
- From the Stroke Unit (J.S.-F., A.G., F.S., C.M., B.R., G.C., L.C.), Centro Hospitalar e Universitário de Coimbra; Faculdade de Medicina da Universidade de Coimbra (J.S.-F., M.C.-B., L.F., L.C.); Centro de Neurociências e Biologia Celular (J.S.-F., S.A., A.C.G., L.F.); Instituto de Ciências Nucleares Aplicadas à Saúde (C.N., M.C., C.F., A.A., M.C.-B.), Coimbra; and Genomics Unit, Biocant-Biotechnology Innovation Center (S.S., A.C.G.), Cantanhede, Portugal.
| |
Collapse
|
10
|
Aday S, Halevy I, Anwar M, Besnier M, Beltrami C, Herman A, Sahoo S, Petretto E, Angelini G, Peer D, Emanueli C. P181Artificial exosomes for post-ischemic vascular regeneration. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p181] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Comune M, Rai A, Chereddy KK, Pinto S, Aday S, Ferreira AF, Zonari A, Blersch J, Cunha R, Rodrigues R, Lerma J, Simões PN, Préat V, Ferreira L. Antimicrobial peptide-gold nanoscale therapeutic formulation with high skin regenerative potential. J Control Release 2017; 262:58-71. [PMID: 28694030 DOI: 10.1016/j.jconrel.2017.07.007] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 07/01/2017] [Accepted: 07/06/2017] [Indexed: 10/19/2022]
Abstract
Chronic skin wounds affect ≈3% of persons aged >60years (Davies et al., 2007) [1]. These wounds are typically difficult to heal by conventional therapies and in many cases they get infected making even harder the regeneration process. The antimicrobial peptide (AMP) LL37 combines antimicrobial with pro-regenerative properties and thus represents a promising topical therapy to address both problems. Here, we investigated the wound healing potential of soluble and immobilized LL37 (LL37-conjugated gold nanoparticles, LL37-Au NPs), both in vitro (migration of keratinocytes) and in vivo (skin wound healing). Our results show that LL37-Au NPs, but not LL37 peptide, have the capacity to prolong the phosphorylation of EGFR and ERK1/2 and enhance the migratory properties of keratinocytes in a large in vitro wound model. We further report that both LL37 and LL37-Au NPs promote keratinocyte migration by the transactivation of EGFR, a process that seems to be initiated at the P2X7 receptor, as confirmed by chemical and genetic inhibition studies. Finally, we show in vivo that LL37-Au NPs have higher wound healing activity than LL37 peptide in a splinted mouse full thickness excisional model. Animal wounds treated by LL37-Au NPs have higher expression of collagen, IL6 and VEGF than the ones treated with LL37 peptide or NPs without LL37. Altogether, the conjugation of AMPs to NPs offers a promising platform to enhance their pro-regenerative properties.
Collapse
Affiliation(s)
- Michela Comune
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Akhilesh Rai
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Kiran K Chereddy
- Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Université Catholique de Louvain, Brussels, Belgium
| | - Sandra Pinto
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Sezin Aday
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - André F Ferreira
- CIEPQPF, Department of Chemical Engineering, University of Coimbra, 3030-790 Coimbra, Portugal
| | - Alessandra Zonari
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Josephine Blersch
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Rodrigo Cunha
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Ricardo Rodrigues
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal
| | - Juan Lerma
- Instituto de Neurociencias, Centro mixto de la Universidad Miguel Hernández de Elche y el Consejo Superior de Investigaciones Científicas, 03550 San Juan de Alicante, Spain
| | - Pedro N Simões
- CIEPQPF, Department of Chemical Engineering, University of Coimbra, 3030-790 Coimbra, Portugal
| | - Veronique Préat
- Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Université Catholique de Louvain, Brussels, Belgium
| | - Lino Ferreira
- CNC-Center for Neurosciences and Cell Biology, University of Coimbra, 3000 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal,.
| |
Collapse
|
12
|
Aday S, Besnier M, Zoldan J, Carreto L, Saif J, Langer R, Emanueli C, Ferreira L. 198 microRNA-17 As The Target of Immobilized Vascular Endothelial Growth Factor in Endothelial Cell Survival Under Ischaemic Conditions. Heart 2016. [DOI: 10.1136/heartjnl-2016-309890.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
13
|
Aday S, Cecchelli R, Hallier-Vanuxeem D, Dehouck MP, Ferreira L. Stem Cell-Based Human Blood-Brain Barrier Models for Drug Discovery and Delivery. Trends Biotechnol 2016; 34:382-393. [PMID: 26838094 DOI: 10.1016/j.tibtech.2016.01.001] [Citation(s) in RCA: 115] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 12/31/2015] [Accepted: 01/04/2016] [Indexed: 12/15/2022]
Abstract
The development of novel neuropharmaceuticals requires the evaluation of blood-brain barrier (BBB) permeability and toxicity. Recent studies have highlighted differences in the BBB among different species, with the most important differences involving the expression of P-glycoprotein (P-gp), multidrug resistance-associated proteins, transporters, and claudins. In addition, functional studies have shown that brain pharmacokinetics of P-glycoprotein substrates are different in humans and rodents. Therefore, human BBB models may be an important platform for initial drug screening before in vivo studies. This strategy might help to reduce costs in drug development and failures in clinical studies. We review the differences in the BBB among species, recent advances in the generation of human BBB models, and their applications in drug discovery and delivery.
Collapse
Affiliation(s)
- S Aday
- Center of Neurosciences and Cell Biology (CNC), University of Coimbra, 3004-517 Coimbra, Portugal; Center of Innovation in Biotechnology (Biocant), 3060-197 Cantanhede, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal
| | - R Cecchelli
- Blood-Brain Barrier Laboratory, Université d'Artois EA 2465, 62307 Lens, France.
| | - D Hallier-Vanuxeem
- Blood-Brain Barrier Laboratory, Université d'Artois EA 2465, 62307 Lens, France
| | - M P Dehouck
- Blood-Brain Barrier Laboratory, Université d'Artois EA 2465, 62307 Lens, France
| | - L Ferreira
- Center of Neurosciences and Cell Biology (CNC), University of Coimbra, 3004-517 Coimbra, Portugal; Center of Innovation in Biotechnology (Biocant), 3060-197 Cantanhede, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal.
| |
Collapse
|
14
|
Aday S, Besnier M, Zoldan J, Saif J, Santos T, Carreto L, Bernardino L, Langer R, Emanueli C, Ferreira L. Abstract 10: MicroRNA 17 in Angiogenesis: Lessons Learned From Immobilized Vascular Endothelial Growth Factor. Circ Res 2015. [DOI: 10.1161/res.117.suppl_1.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Several pre-clinical and clinical studies are exploring the therapeutic effect of cell-based therapies in ischemic diseases, including Peripheral Artery Disease (PAD). Unfortunately, most of the cells (more than 80%) die few days after delivery. We postulate that better understanding of VEGF Biology might be important for the design of more effective pro-survival strategies. Release of VEGF from ECM activates a carcinogenic program since it triggers vasculogenesis, tumor growth and metastasis. Contrarily, immobilized VEGF might have all the properties of soluble VEGF without inducing a carcinogenic program. Thus, identification of downstream players such as miRNAs mediating this process might be important. Herein, we evaluated therapeutic effect of miR-17 downregulation, which mediates the effect of immobilized VEGF both in vitro and in vivo.
We recently showed that conjugated VEGF modulates cell activity by decreasing the expression miR-17 both in vitro and in vivo. In the present study, cell survival and angiogenesis were evaluated firstly in vitro using endothelial cells (ECs) transfected with antagomiR-17 to mimic the down-regulation of miR-17 by conjugated VEGF. AntagomiR-17 increased EC survival at least 1.5 times (n=6) compared to pro-angiogenic miRNAs reported in the literature (e.g. miR-424 and miR-132) and sprout formation on Matrigel at least 2 times (n=5) compared to all groups. The effect of antagomiR-17 was more pronounced under hypoxia conditions. In vivo, antagomiR-17 accelerated hemodynamic recovery of the whole limb (n=12) in unilateral limb ischemia obtained by occlusion of the left femoral artery. Blood flow recovery evaluated by Laser Doppler analysis was significantly higher 21 days after surgery in antagomiR-17 group compared to all other groups. Immunohistochemical analyses showed an increase in the capillary density of skeletal muscle in antagomiR-17 condition. In order to determine the gene target and potential pathway involved in the biological effect of antagomiR-17, next generation mRNA sequencing was performed.
In conclusion, here we show the potential and underlying molecular mechanism of antagomiR-17 treatment in endothelial cell survival and angiogenesis both in vitro and in vivo.
Collapse
Affiliation(s)
- Sezin Aday
- CNC-Cntr for Neuroscience and Cell Biology, Coimbra, Portugal
| | - Marie Besnier
- Bristol Heart Institute, Sch of Clinical Sciences, Univ of Bristol, Bristol, United Kingdom
| | - Janet Zoldan
- Massachusetts Institute of Technology, Cambridge, MA
| | - Jaimy Saif
- Bristol Heart Institute, Sch of Clinical Sciences, Univ of Bristol, Bristol, United Kingdom
| | | | | | | | - Robert Langer
- Massachusetts Institute of Technology, Cambridge, MA
| | - Costanza Emanueli
- Bristol Heart Institute, Sch of Clinical Sciences, Univ of Bristol, Bristol, United Kingdom
| | - Lino Ferreira
- CNC-Cntr for Neuroscience and Cell Biology, Coimbra, Portugal
| |
Collapse
|
15
|
Aday S, Paiva J, Sousa S, Gomes RSM, Pedreiro S, So PW, Carr CA, Cochlin L, Gomes AC, Paiva A, Ferreira L. Inflammatory modulation of stem cells by Magnetic Resonance Imaging (MRI)-detectable nanoparticles. RSC Adv 2014. [DOI: 10.1039/c4ra04041d] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Novel MRI-detectable PLGA nanoparticles can track hematopoietic stem cells and down-regulate the secretion of pro-inflammatory cytokines by interfering with TLRs.
Collapse
Affiliation(s)
- Sezin Aday
- CNC – Center for Neurosciences and Cell Biology
- University of Coimbra
- Coimbra, Portugal
- Biocant
- Biotechnology Innovation Center
| | - Jose Paiva
- CNC – Center for Neurosciences and Cell Biology
- University of Coimbra
- Coimbra, Portugal
- Biocant
- Biotechnology Innovation Center
| | - Susana Sousa
- Biocant
- Biotechnology Innovation Center
- , Portugal
| | - Renata S. M. Gomes
- King's BHF Centre of Excellence
- Cardiovascular Proteomics
- King's College London
- London, UK
| | | | - Po-Wah So
- Department of Neuroimaging
- Institute of Psychiatry
- King's College London
- London, UK
| | - Carolyn Ann Carr
- Cardiac Metabolism Research Group
- Department of Physiology, Anatomy & Genetics
- University of Oxford
- UK
| | | | | | - Artur Paiva
- Centro de Histocompatibilidade do Centro
- Coimbra, Portugal
| | - Lino Ferreira
- CNC – Center for Neurosciences and Cell Biology
- University of Coimbra
- Coimbra, Portugal
- Biocant
- Biotechnology Innovation Center
| |
Collapse
|
16
|
Türkoğlu Şaşmazel H, Aday S, Manolache S, Gümüşderelioğlu M. Influence of water/O₂ plasma treatment on cellular responses of PCL and PET surfaces. Biomed Mater Eng 2011; 21:123-37. [PMID: 21654068 DOI: 10.3233/bme-2011-0662] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In this study, low pressure water/O₂ plasma treatment was performed in order to obtain COOH functionalities on the surface of poly-ε-caprolactone (PCL) membranes as well as non-woven polyester fabric (NWPF) discs. The plasma treatments were performed in a cylindrical, capacitively coupled RF-plasma-reactor and then following steps were performed: in situ (oxalyl chloride vapors) gas/solid reaction to convert -OH functionalities into -COCl groups; and hydrolysis under open laboratory conditions using air moisture for final-COOH functionalities. COOH and OH functionalities on modified surfaces were detected quantitatively by using fluorescent labeling technique and an UVX 300G sensor. Electron spectroscopy for chemical analysis (ESCA) was used to evaluate the relative surface atomic compositions and the carbon and oxygen linkages located in non-equivalent atomic positions of untreated and modified surfaces. Atomic force microscope (AFM) analysis showed that nanoscale features of the PCL surfaces are dramatically changed during the surface treatments. Scanning electron microscopy (SEM) results indicated the changes in the relatively smooth appearance of the untreated NWPF discs after the plasma treatment. Periodontal ligament (PDL) fibroblasts were used in cell culture studies. Cell culture results showed that plasma treated PCL membranes and NWPF discs were favorable for the PDL cell spreading, growth and viability due to the presence of functional groups and/or nanotopographies on their surfaces.
Collapse
Affiliation(s)
- Hilal Türkoğlu Şaşmazel
- Metallurgical and Materials Engineering Department, Atilim University, Incek, Golbasi 06836 [corrected] Ankara, Turkey
| | | | | | | |
Collapse
|
17
|
|
18
|
Maia J, Santos T, Aday S, Agasse F, Cortes L, Malva JO, Bernardino L, Ferreira L. Controlling the neuronal differentiation of stem cells by the intracellular delivery of retinoic acid-loaded nanoparticles. ACS Nano 2011; 5:97-106. [PMID: 21171566 DOI: 10.1021/nn101724r] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The manipulation of endogenous stem cell populations from the subventricular zone (SVZ), a neurogenic niche, creates an opportunity to induce neurogenesis and influence brain regenerative capacities in the adult brain. Herein, we demonstrate the ability of polyelectrolyte nanoparticles to induce neurogenesis exclusively after being internalized by SVZ stem cells. The nanoparticles are not cytotoxic for concentrations equal or below 10 μg/mL. The internalization process is rapid, and nanoparticles escape endosomal fate in a few hours. Retinoic acid-loaded nanoparticles increase the number of neuronal nuclear protein (NeuN)-positive neurons and functional neurons responding to depolarization with KCl and expressing NMDA receptor subunit type 1 (NR1). These nanoparticles offer an opportunity for in vivo delivery of proneurogenic factors and neurodegenerative disease treatment.
Collapse
Affiliation(s)
- João Maia
- Chemical Engineering Department, University of Coimbra, Pinhal de Marrocos, 3030-290 Coimbra, Portugal
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Sasmazel HT, Aday S, Manolache S, Gumusderelioglu M. Influence of water/O2 plasma treatment on cellular responses of PCL and PET surfaces. Biomed Mater Eng 2011. [DOI: 10.3233/bme-2011-0668] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Türkoğlu Saşmazel H, Aday S, Gümüşderelioğlu M. Insulin and heparin co-immobilized 3D polyester fabrics for the cultivation of fibroblasts in low-serum media. Int J Biol Macromol 2007; 41:338-45. [PMID: 17576003 DOI: 10.1016/j.ijbiomac.2007.04.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2006] [Revised: 04/25/2007] [Accepted: 04/25/2007] [Indexed: 11/22/2022]
Abstract
Insulin and/or heparin immobilized/co-immobilized non-woven polyester fabric (NWPF) discs were developed for the cultivation of L929 mouse fibroblasts in low-serum media. At first, NWPF discs were hydrolyzed to obtain a carboxylic acid group-introduced matrix (NWPF-hydrolyzed). Insulin and heparin co-immobilized NWPF (NWPF-insulin-heparin) was prepared by the grafting of PEO onto NWPF-hydrolyzed disc (NWPF-PEO), followed by the reaction first with insulin and then heparin. In the presence of spacer arm, PEO, the amount of immobilized insulin molecules significantly increased from 6.96 to 84.45 microg/cm(2). The amount of heparin bound to the NWPF-PEO (5.93 microg/cm(2)) was higher than that of the insulin immobilized surface (4.59 microg/cm(2)). Insulin and heparin immobilized NWPF discs were observed with fluorescence microscopy by labeling the insulin and heparin with 8-anilino-1-naphthalene sulfonic acid (ANS) or fluorescein isothiocyanate (FITC), respectively. L929 fibroblasts were used to check the cell adhesion and cell growth capabilities of modified NWPF discs in low-serum media (containing 5% fetal bovine serum). Optical photographs showed that after 2nd day of the culture, fibroblastic cells spread along the length of modified fibers, eventually filling the interfiber space. At the end of 6-day growth period, cell yield in the presence of immobilized heparin was a little bit higher than that of the immobilized insulin. Co-immobilized (insulin/heparin) NWPF discs did not accelerate the cell growth as well as insulin or heparin immobilized discs.
Collapse
Affiliation(s)
- Hilal Türkoğlu Saşmazel
- Hacettepe University, Chemical Engineering and Bioengineering Departments, 06800 Beytepe, Ankara, Turkey
| | | | | |
Collapse
|